In the BioHarmony Drug Report Database
Methysergide
Sansert (methysergide) is a small molecule pharmaceutical. Methysergide was first approved as Sansert on 1982-01-01. It is used to treat vascular headaches in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2B. In addition, it is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 5A.
Trade Name
|
Sansert |
|---|---|
Common Name
|
methysergide |
ChEMBL ID
|
CHEMBL485253 |
Indication
|
vascular headaches |
Drug Class
|
Ergot alkaloid derivatives |
Image (chem structure or protein)